Targets: The usual RT-PCR assay for COVID-19 is laborious and time-consuming, limiting the supply of testing. Fast antigen-detection exams are sooner and cheaper; nonetheless, the reliability of those exams should be validated earlier than they can be utilized extensively. The target of this research was to find out the efficiency of the Panbio^TM COVID-19 Ag Fast Take a look at Gadget (PanbioRT) (Abbott) for SARS-CoV-2 in nasopharyngeal swab specimens.

Strategies: This potential multicenter research was carried out in ten Spanish college hospitals together with people with scientific signs or epidemiological standards for COVID-19. Solely people with ≤ 7 days from the onset of signs or from publicity to a confirmed case of COVID-19 have been included. Two nasopharyngeal samples have been taken to carry out the PanbioRT, as a point-of-care take a look at, and a diagnostic RT-PCR take a look at.

Outcomes: Among the many 958 sufferers studied, 325 (90.5%) had true-positives outcomes. The general sensitivity and specificity for the PanbioRT have been 90.5% (CI 95%: 87.5-93.6) and 98.8% (CI 95%: 98-99.7), respectively. Sensitivity in contributors who had a C_T <25 for the RT-PCR take a look at was 99.5% (CI 95%: 98.4-100), and in contributors with ≤5 days of the scientific course was 91.8% (CI 95%: 88.8-94.8). Settlement between methods was 95.7% (kappa rating: 0.90; CI 95%: 0.88-0.93).

Conclusions: The PanbioRT supplies good scientific efficiency, with much more dependable outcomes for sufferers with a shorter scientific course of the illness or the next viral load. The outcomes should be interpreted based mostly on the native epidemiological context.

Targets: We aimed to guage the accuracy of the Panbio™ Ag-RDT at main well being care (PHC) facilities and take a look at websites in symptomatic sufferers and shut contacts, utilizing the Reverse-Transcription Polymerase Chain Response (RT-PCR) take a look at because the gold normal.

Strategies: The research was carried out in 4 PHC facilities and two take a look at websites in Mallorca, Spain. Consecutive sufferers older than 18 years, attending the websites for RT-PCR testing have been included. Two nasopharyngeal samples have been collected, one for RT-PCR and the opposite was processed on-site utilizing the Panbio fast antigen take a look at equipment for SARS-CoV-2. The sensitivity and specificity have been calculated utilizing RT-PCR because the reference, and the predictive values utilizing the pretest likelihood outcomes for every analyzed group.

Findings: A complete of 1369 contributors have been included; imply age 42.5 ± 14.9 years and 54.3% ladies. The general prevalence was 10.2%. Most contributors (70.6%) introduced inside 5 days of the onset of signs.

The general sensitivity was of 71.4% (95% CI: 63.1%, 78.7%), the specificity of 99.8% (95% CI: 99.4%, 99.9%), the constructive predictive worth of 98.0% (95% CI: 93.0%, 99.7%) and a destructive predictive worth of 96.8% (95% CI: 95.7%, 97.7%). The sensitivity was larger in symptomatic sufferers, in these arriving inside 5 days since symptom onset and in these with excessive viral load.

Interpretation: Ag-RDT had comparatively good efficiency traits in suspected symptomatic sufferers inside 5 days for the reason that onset of signs. Nevertheless, our knowledge don’t help the only real use of Panbio™ Ag-RDT in asymptomatic people.

Background: RT-qPCR is the reference take a look at for identification of energetic SARS-CoV-2 an infection, however is related to diagnostic delay. Antigen detection assays can generate outcomes inside 20 min and outdoors of laboratory settings. But, their diagnostic take a look at efficiency in actual life settings has not been decided.

Strategies: The diagnostic worth of the Panbio™ COVID-19 Ag Fast Take a look at (Abbott), was decided compared to RT-qPCR (Seegene Allplex) in community-dwelling mildly symptomatic topics in a medium (Utrecht, the Netherlands) and excessive endemic space (Aruba), utilizing two concurrently obtained nasopharyngeal swabs.Findings: 1367 and 208 topics have been enrolled in Utrecht and Aruba, respectively. SARS-CoV-2 prevalence, based mostly on RT-qPCR, was 10.2% (n = 139) and 30.3% (n = 63) in Utrecht and Aruba respectively.

The specificity of the Panbio™ COVID-19 Ag Fast Take a look at was 100% (95%CI: 99.7-100%) in each settings. Take a look at sensitivity was 72.6% (95%CI: 64.5-79.9%) within the Netherlands and 81.0% (95% CI: 69.0-89.8%) in Aruba. Likelihood of false destructive outcomes was related to RT-qPCR Ct-values, however not with period of signs. Limiting RT-qPCR take a look at positivity to Ct-values <32 yielded take a look at sensitivities of 95.2% (95%CI: 89.3-98.5%) in Utrecht and 98.0% (95%CI: 89.2-99.95%) in Aruba.

Interpretation: In community-dwelling topics with gentle respiratory signs the Panbio™ COVID-19 Ag Fast Take a look at had 100% specificity, and a sensitivity above 95% for nasopharyngeal samples when utilizing Ct-values <32 cycles as cut-off for RT-qPCR take a look at positivity. Contemplating quick turnaround instances, person friendliness, low prices and alternatives for decentralized testing, this take a look at can enhance our efforts to manage transmission of SARS-CoV-2.

Targets: There’s restricted data on the efficiency of fast antigen detection (RAD) exams to determine SARS-CoV-2-infected asymptomatic people. On this discipline research, we evaluated the Panbio™ COVID-19 Ag Fast Take a look at Gadget (Abbott Diagnostics, Jena, Germany) for this function.

Strategies: A complete of 634 people (355 feminine; median age, 37 years; vary, 9-87) have been enrolled. Two nasopharyngeal swabs have been collected from family (n=338) and non-household contacts (n=296) of COVID-19 circumstances. RAD testing was carried out on the level of care. The RT-PCR take a look at used was the TaqPath COVID-19 Combo Package (Thermo Fisher Scientific, Massachusetts, USA).

Outcomes: Family contacts have been examined at a median of two days (vary, 1-7) after prognosis of the index case, whereas non-household contacts (n=296) have been examined at a median of 6 days (vary, 1-7) after publicity. In complete, 79 people (12.4%) examined constructive by RT-PCR, of whom 38 (48.1%) yielded constructive RAD outcomes. The general sensitivity and specificity of the RAD take a look at was 48.1% (95% CI: 37.4-58.9) and 100% (95% CI: 99.3-100), respectively. Sensitivity was larger in family (50.8%; 95% CI: 38.9-62.5) than in non-household (35.7%; 95% CI:16.3-61.2%) contacts. People testing constructive by RAD take a look at have been extra seemingly (P<0.001) to develop into symptomatic than their destructive counterparts.

Conclusion: The Panbio take a look at shows low sensitivity in asymptomatic shut contacts of COVID-19 sufferers, significantly in non-household contacts. Nonetheless, establishing the optimum timing for higher respiratory tract assortment on this group appears crucial to pinpoint take a look at sensitivity.

Targets: To our information no earlier research has assessed the efficiency of a fast antigen diagnostic immunoassay (RAD) carried out on the level of care (POC). We evaluated the Panbio™ COVID-19 Ag Fast Take a look at Gadget for COVID-19 prognosis in symptomatic sufferers (n=412) attended in main healthcare facilities.

Strategies: RAD was carried out instantly after sampling following the producer’s directions (studying at 15 min.). RT-PCRs have been carried out inside 24 h. of specimen assortment. Samples displaying discordant outcomes have been processed for tradition in Vero E6 cells. Presence of SARS-CoV-2 in cell cultures was confirmed by RT-PCR.

Outcomes: Out of 412 sufferers, 43 (10.4%) examined constructive by RT-PCR and RAD and 358 (86.9%) destructive by each strategies, exhibiting discordant outcomes (RT-PCR+/RAD-) in 11 sufferers (2.7%). General specificity and sensitivity of fast antigen detection (RAD) was 100% (95% CI, 98.7-100%), and 79.6% (95% CI, 67.-88.8%), respectively, taking RT-PCR because the reference.

General RAD destructive predictive worth for an estimated prevalence of 5% and 10% was 99% (95% CI, 97.4-99.6%) and 97.9% (95% CI, 95.9-98.9), respectively. SARS-CoV-2 couldn’t be cultured from specimens yielding RT-PCR+/RAD-results (n=11).

Conclusion: The Panbio COVID-19 Ag Fast Take a look at Gadget carried out nicely as a POCT for early prognosis of COVID-19 in main healthcare facilities. Extra crucially, the information advised that sufferers with RT-PCR-proven COVID-19 testing destructive by RAD are unlikely to be infectious.

KIR2DL4
pro-2460	ProSpec Tany	1µg	EUR 60
Description: Recombinant Human Killer Cell Immunoglobulin-Like Receptor, 2 Domains Long Cytoplasmic Tail 4

Human KIR2DL4 ELISA KIT
ELI-21303h	Lifescience Market	96 Tests	EUR 988.8

Human KIR2DL4 shRNA Plasmid
20-abx952576	Abbexa	EUR 961.20 EUR 1345.20	150 µg 300 µg

KIR2DL4 antibody
70R-2365	Fitzgerald	50 ug	EUR 560.4
Description: Rabbit polyclonal KIR2DL4 antibody raised against the middle region of KIR2DL4

KIR2DL4 Antibody
DF13591	Affinity Biosciences	100ul	EUR 280
Description: Human,Rat

KIR2DL4 Antibody
E309374	EnoGene	200ul	EUR 275
Description: Available in various conjugation types.

KIR2DL4 Antibody
E912836	EnoGene	100ul	EUR 255
Description: Available in various conjugation types.

KIR2DL4 Antibody
DF13591-100ul	Affinity Biosciences	100ul	EUR 280

KIR2DL4 Antibody
DF13591-200ul	Affinity Biosciences	200ul	EUR 350

Human KIR2DL4 Protein, Fc Tag
E40KMPH4155	EnoGene	20ug	EUR 495

Human KIR2DL4 Protein, Fc Tag
E40KMPH4156	EnoGene	20ug	EUR 495

KIR2DL4 Recombinant Protein (Human)
RP017041	ABM	100 ug	Ask for price

NE Purified anti-human CD158d (KIR2DL4)
E16FHY158d-050U	EnoGene	50 μg	EUR 845
Description: Available in various conjugation types.

KIR2DL4 ORF Vector (Human) (pORF)
ORF005681	ABM	1.0 ug DNA	EUR 114

KIR2DL4 siRNA
20-abx921662	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

Human KIR2DL4 Protein Lysate 20ug
IHUKIR2DL4PLLY20UG	Innovative research	each	EUR 213
Description: Human KIR2DL4 Protein Lysate 20ug

KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody
20-abx210854	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody
20-abx339417	Abbexa	EUR 493.20 EUR 360.00	100 ul 50 ul

KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody
1-CSB-PA205578	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody
1-CSB-PA246816	Cusabio	EUR 380.40 EUR 292.80	100ul 50ul
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:50-1:100

Human KIR2DL4 / CD158d Protein, Fc Tag
KI4-H5255	ACROBIOSYSTEMS	100ug	EUR 2749.9
Description: Human KIR2DL4, Fc Tag (KI4-H5255) is expressed from human 293 cells (HEK293). It contains AA His 24 - His 242 (Accession # Q99706-1).

KIR2DL4 Polyclonal Antibody
27806-100ul	SAB	100ul	EUR 302.4

KIR2DL4 Polyclonal Antibody
27806-50ul	SAB	50ul	EUR 224.4